Inflammation and insulin resistance

Diabetes Care

Volumn 26, Issue 6, 2003, Pages 1922-1926

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; AUTOANTIBODY; BETA CAROTENE; C REACTIVE PROTEIN; CATALASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FASUDIL; GLUCOSE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PEROXYNITRITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROTEIN KINASE C; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INTENSIVE CARE UNIT; MORTALITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; RESTENOSIS; REVIEW;

CORONARY DISEASE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; ISLETS OF LANGERHANS; T-LYMPHOCYTES;

EID: 0042031531     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.6.1922     Document Type: Review

References (49)

1. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
2. Dowse GK: Incidence of type 2 diabetes and the natural history of IGT in Pacific and Indian Ocean populations. Diabetes Res Clin Pract 34 (Suppl.):545-550, 1996
3. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-type 2 diabetes randomized trial. Lancet 359:2072-2077, 2002
5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
6. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglvcemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
7. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191-196, 2001
8. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2638, 2001
9. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783-1790, 1997
10. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
11. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D: Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 268:E1167-E1173, 1995
12. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44:834-838, 2001
13. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108:635-636, 2001
14. Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 18:756-760, 2001
15. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22:1245-1251, 1999
16. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J, et al: Effects of α-tocopherol and β-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62:1427S-1430S, 1995
17. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 347:781-786, 1996
18. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE: Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 107:947-953, 20.03
19. de Gaetano G: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357:89-95, 2001
20. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P: Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomized trial. Lancet 359:1108-1113, 2002
21. Kaul N, Devaraj S, Grundy SM, Jialal I: Failure to demonstrate a major anti-inflammatory effect with alpha tocopherol supplementation (400 IU/day) in normal subjects. Am J Cardiol 87:1320-1323, 2001
22. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354:447-455, 1999
23. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:154-160, 2000
24. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 23-33, 2002
25. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297, 1999
26. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
27. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto I: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69-75, 1998
28. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
29. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014-1019, 2000
30. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144, 2002
31. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
32. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Culi CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
33. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
34. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25: 1177-1184, 2002
35. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000
36. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease before clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129-1134, 2002
37. Glass CK, Witztum JL: Atherosclerosis: the road ahead. Cell 104:503-516, 2001
38. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, Malinski T: Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 101:1261-1266, 2000
39. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287:3215-3222, 2002
40. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341:70-76, 1999
41. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92: 3172-3177, 1995
42. Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ: Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 81:963-969, 1997
43. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, Rifai N, Carlson W, Lloyd-Jones DM, Johnstone M, Rubenstein J, Alexander S, Orav J, Stone PH: Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89:1205-1207, 2002
44. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547, 2002
45. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960, 2001
46. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI: The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A 97:9052-9057, 2000
47. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators: lnvasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 354:708-715, 1999
48. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
49. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001